FINWIRES · TerminalLIVE
FINWIRES

Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Phase 3 Trial; Shares Fall Pre-Bell

By

Novo Nordisk (NVO) said Friday its drug candidate, ziltivekimab, did not reduce major adverse cardiovascular events in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation compared with a placebo in a phase 3 trial.

The trial evaluated once-monthly ziltivekimab 15 mg compared with placebo for rreducing the risk of major adverse cardiovascular events, or MACE, which are defined as cardiovascular death, non-fatal heart attack or non-fatal stroke.

The company said two additional ongoing cardiovascular outcome trials evaluating the drug candidate in people with heart failure an in people following an acute heart attack will continue and are expected to read out their results in H1 2027.

Shares of Novo Nordisk fell more than 10% in recent premarket activity Friday.

Price: $46.26, Change: $-5.35, Percent Change: -10.37%

Related Articles

Wire

Update: BHP Group Faces Strike Action in Western Australia's Pilbara

(Updates to add BHP's statement in the fourth and fifth paragraphs and share movement in the last paragraph)BHP Group (ASX:BHP) is facing another strike from members of three unions in Western Australia's Pilbara region who have decided to impose a 24-hour ship-loading ban on Aug. 8 and will also down tools on Aug. 9, according to multiple media reports on Friday.According to an Australian Financial Review report, the company expects that a work stoppage at Port Hedland will impact AU$120 million in revenue per day.The combined union decision comes after a failed strike over pay disputes that took place on July 16, which was not attended by enough workers to cause a serious disruption.In response to' request for comment, a BHP spokesperson said that the company has plans in place to continue operations despite the potential disruptions.The company has a formal meeting convened by the Fair Work Commission scheduled for next Tuesday to progress bargaining and will seek further assistance from the Commission if needed, the spokesperson added.The company's shares rose almost 2% in recent Friday trade.

ASX:BHP
Wire

Cohu Q2 Adjusted Earnings, Revenue Rise; Shares Jump After Hours

Cohu (COHU) reported Q2 adjusted earnings late Thursday of $0.26 per diluted share, up from $0.02 a year earlier.Analysts polled by FactSet expected $0.14.Revenue for the quarter ended June 27 rose to $149 million from $107.7 million a year ago.Analysts projected $144.2 million.Cohu expects Q3 revenue of $170 million, plus or minus $7 million.Analysts project $146.4 million.Cohu shares jumped 21% in after-hours trading.

$COHU
Wire

Western Union Q2 Adjusted Earnings, Revenue Fall; Cuts 2026 Outlook

Western Union (WU) reported Q2 adjusted earnings Thursday of $0.31 per diluted share, down from $0.42 a year earlier.Analysts polled by FactSet expected $0.42.Revenue for the quarter ended June 30 was $1.01 billion, compared with $1.03 billion a year earlier.Analysts expected $1.02 billion.The company now expects 2026 adjusted EPS of $1.25 to $1.35, down from $1.75 to $1.85. Analysts expect $1.72.Full-year revenue is now expected to grow 3% to 5%, compared with 5% to 8% expected earlier.

$WU